We are live on
!
Find out more
SFM
Sphera Funds Management Portfolio holdings
AUM
$630M
1-Year Est. Return
108.65%
This Fund
S&P 500
This Quarter
Est. Return
-4.24%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$733M
AUM Growth
+$21.5M
(+3%)
Cap. Flow
+$93.1M
Cap. Flow
% of AUM
12.7%
Top 10 Holdings %
Top 10 Hldgs %
32.84%
Holding
138
New
34
Increased
32
Reduced
32
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$25.7M |
| 2 |
Skye Bioscience
SKYE
|
+$15.4M |
| 3 |
ASML
ASML
|
+$9.52M |
| 4 |
Salesforce
CRM
|
+$8.99M |
| 5 |
BridgeBio Pharma
BBIO
|
+$8.86M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$16.9M |
| 2 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
+$9.57M |
| 3 |
Camtek
CAMT
|
+$6.97M |
| 4 |
Perspective Therapeutics
CATX
|
+$6.61M |
| 5 |
NVMI
Nova
NVMI
|
+$6.23M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 59.43% |
| 2 | Technology | 17.13% |
| 3 | Communication Services | 3.05% |
| 4 | Consumer Discretionary | 3% |
| 5 | Utilities | 0.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
FIVE9
FIVN
$2.11B
| – | – |
-27,500
| Closed | -$1.71M |
|
127
Geron
GERN
$828M
| – | – |
-384,356
| Closed | -$1.27M |
|
128
Incyte
INCY
$24.2B
| – | – |
-89,556
| Closed | -$5.1M |
|
129
CALL
Insmed
INSM
$21.4B
| – | – |
-28,100
| Closed | -$762K |
|
130
CALL
Disc Medicine
IRON
$2.96B
| – | – |
-25,000
| Closed | -$1.56M |
|
|
NVMI
131
Nova
NVMI
$12.4B
| – | – |
-35,106
| Closed | -$6.23M |
|
132
CALL
Ultragenyx Pharmaceutical
RARE
$2.45B
| – | – |
-55,000
| Closed | -$2.57M |
|
133
CALL
SolarEdge
SEDG
$2.51B
| – | – |
-26,800
| Closed | -$1.9M |
|
|
134
SolarEdge
SEDG
$2.51B
| – | – |
-40,175
| Closed | -$2.85M |
|
135
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.95B
| – | – |
-380,000
| Closed | -$36.1M |
|
136
Alto Neuroscience
ANRO
$1.05B
| – | – |
-30,500
| Closed | -$468K |
|
|
FUSN
137
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| – | – |
-449,041
| Closed | -$9.57M |
|
|
ALPN
138
DELISTED
Alpine Immune Sciences Inc
ALPN
| – | – |
-44,841
| Closed | -$1.78M |
|
Similar funds
VIM
KCMH
FCFC
BI
PWW
TTSTC
SWP
EIM
Sphera Funds Management's Q2 2024 Portfolio in Review
As of Q2 2024, Sphera Funds Management held 138 positions worth $733M, up 3% from $712M the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Sphera Funds Management deployed $93.1M of net new capital in Q2 2024, opening 34 new positions and adding to 32 existing holdings. Its largest new stake was Skye Bioscience: 1,298,312 shares worth $10.4M.
By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 65% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $16.9M trimmed.
- Sphera Funds Management's largest Q2 2024 buy was Skye Bioscience: 1,298,312 shares worth $10.4M.
- Sphera Funds Management added most to Broadcom in Q2 2024, an estimated $25.7M increase.
- Sphera Funds Management's biggest Q2 2024 reduction was Teva Pharmaceuticals, cutting an estimated $16.9M.
- Sphera Funds Management fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $9.57M.
- Sphera Funds Management's ten largest holdings make up 33% of its $733M portfolio in Q2 2024.
- Sphera Funds Management opened 34 new positions and closed 20 in Q2 2024.
- Sphera Funds Management's portfolio value rose 3% quarter-over-quarter to $733M.
Based on Sphera Funds Management's 13F filing for Q2 2024, filed 14 Aug 2024.